Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Metformin effect on a cohort of non-diabetic patients with early breast cancer in a window of opportunity study

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Maasumeh Saberian

Citation

Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519

Authors

S. Sadighi, M. Najafi, M.S. Saberian, I. Jahanzad, R. Omranipoor

Author affiliations

  • Medical Oncology, Cancer Institute, 1419733141 - Tehran/IR
More

Resources

Aim/Background

We design a prospective controlled study about metformin efficacy in the window time between biopsy and definite surgery with changes of Ki67 as the primary endpoint.

Methods

Non-diabetic patients with invasive breast cancer accrued in Medical Oncology Department of Iran Cancer Institute from Feb to Nov 2014. They followed between biopsy and definitive surgery, taking tests on pathology specimens for ER, PgR, HER2 and KI67. We checked fasting blood insulin and sugar level as well as quality of life and adverse effects in both times. Metformin (1500 mg/day) was prescribed to intervention group from pathology report to the night before surgery. Control group were patients with the same inclusion criteria who did not receive any drug between biopsy and surgery.

Results

From 50 patients enrolled 5 excluded. Four without using any pills and one at the first day of taking metformin; 25 had been received metformin for median time of 2.8 weeks. Controlled group included 20 patients. There were no statistically significant differences between two groups regarding baseline clinical and tumor characteristics such as age, stage, grade, Er, Pgr, HER2 status, time and type of surgery. However, immunohistochemistry study showed decrease of median KI67 from 35.14 to 29.6 in the intervention group and increase in the control group. The diference was statistically significant. Patients tolerated metformin very well. There was a correlation between metabolic factor of HOMA score (fasting insulin level*fasting blood sugar/405) and changes in KI67.

Conclusions

Metformin prescription between Biopsy and definite surgery had shown inhibition of breast cancer proliferation index. We found relationship this effect and glucose and insulin metabolism.

Clinical trial identification

Cancer Research Center on Iran Cancer Institute under observation of Research Deputy of Tehran U Medical Sciences approved proposal at Dec

2012

Disclosure

study funded by Research Deputy of Tehran U Medical School.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings